nach oben

Die Urologie

Erschienen in:

01.04.2014 | Leitthema

Molekulare multimodale Hybridbildgebung des Prostata- und Blasenkarzinoms

verfasst von: PD Dr. T. Maurer, M. Eiber, B.J. Krause

Erschienen in: Die Urologie | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Seit Einführung der kombinierten radiologisch-nuklearmedizinischen Bildgebung in Form der Positronenemissionstomographie/Computertomographie (PET/CT) und unlängst auch der PET/Magnetresonanztomographie (PET/MRT) stehen beim Blasen- und Prostatakarzinom neue und z. T. vielversprechende diagnostische Möglichkeiten zur Verfügung. Während beim Blasenkarzinom die PET-basierte Hybridbildgebung bisher nur in ausgewählten Fällen zur Anwendung kommt, zeichnet sich eine Zunahme der PET-Diagnostik beim Prostatakarzinom mit der Entwicklung karzinomspezifischer PET-Tracer ab. Besonders neuartige Liganden des prostataspezifischen Membranantigens (PSMA) besitzen hierbei das Potential, das zukünftige Staging des Prostatakarzinoms nachhaltig zu beeinflussen. Bevor jedoch ein breiter Einsatz in der Routine empfohlen werden kann, sollte eine Evaluierung im Rahmen von prospektiven multizentrischen klinischen Studien erfolgen.

Afshar-Oromieh A, Haberkorn U, Eder M et al (2012) [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 39:1085–1086PubMedCrossRef

Akduman EI, Momtahen AJ, Balci NC et al (2008) Comparison between malignant and benign abdominal lymph nodes on diffusion-weighted imaging. Acad Radiol 15:641–646PubMedCrossRef

AWMF (2011) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. AWMF, Düsseldorf

Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746–757PubMedCentralPubMedCrossRef

Beer AJ, Eiber M, Souvatzoglou M et al (2011) Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 13:352–361PubMedCrossRef

Beheshti M, Haim S, Zakavi R et al (2013) Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 54:833–840PubMedCrossRef

Boonsirikamchai P, Choi S, Frank SJ et al (2013) MR imaging of prostate cancer in radiation oncology: what radiologists need to know. Radiographics 33:741–761PubMedCrossRef

Bouchelouche K, Turkbey B, Choyke PL (2012) PET/CT and MRI in Bladder Cancer. J Cancer Sci Ther S14, doi:10.4172/1948-5956

Breeuwsma AJ, Rybalov M, Leliveld AM et al (2012) Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy. Q J Nucl Med Mol Imaging 56:440–446PubMed

10.

Brogsitter C, Zophel K, Kotzerke J (2013) 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging 40(Suppl 1):18–27CrossRef

11.

Bücheler E, Lackner KL, Thelen M (2006) Einführung in die Radiologie, Diagnostik und Intervention, 11. Aufl. Thieme, Stuttgart, S 606

12.

Bundschuh RA, Wendl CM, Weirich G et al (2013) Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging 40:824–831PubMedCrossRef

13.

Ceci F, Castellucci P, Mamede M et al (2013) (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging 40:149–155PubMedCrossRef

14.

Daneshmand S, Ahmadi H, Huynh LN et al (2012) Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology 80:1313–1318PubMedCrossRef

15.

Eiber M, Beer AJ, Holzapfel K et al (2010) Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 45:15–23PubMedCrossRef

16.

Eiber M, Holzapfel K, Ganter C et al (2011) Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging 33:1160–1170PubMedCrossRef

17.

Eiber M, Souvatzoglou M, Maurer T et al (2013) Initial experience in restaging of patients with recurrent prostate cancer: comparison of 11C-Choline-PET/MR and 11C-Choline-PET/CT. Soc Nucl Med Annu Meet Abstr 5:343

18.

Eschmann SM, Pfannenberg AC, Rieger A et al (2007) Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 46:161–168PubMed

19.

Evangelista L, Guttilla A, Zattoni F et al (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63:1040–1048PubMedCrossRef

20.

Evangelista L, Zattoni F, Guttilla A et al (2013) Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 38:305–314PubMedCrossRef

21.

Even-Sapir E, Metser U, Mishani E et al (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287–297PubMed

22.

Fuccio C, Castellucci P, Schiavina R et al (2012) Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol 81:893–896CrossRef

23.

Fuccio C, Castellucci P, Schiavina R et al (2010) Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 24:485–492PubMedCrossRef

24.

Fuccio C, Schiavina R, Castellucci P et al (2011) Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 38:1985–1989PubMedCrossRef

25.

Giannarini G, Nguyen DP, Thalmann GN et al (2012) Diffusion-weighted magnetic resonance imaging detects local recurrence after radical prostatectomy: initial experience. Eur Urol 61:616–620PubMedCrossRef

26.

Giovacchini G, Picchio M, Garcia-Parra R et al (2014) 11C-Choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. J Nucl Med (Epub ahead of print)

27.

Giovacchini G, Picchio M, Parra RG et al (2012) Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med 37:325–331PubMedCrossRef

28.

Gofrit ON, Mishani E, Orevi M et al (2006) Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 176:940–944PubMedCrossRef

29.

Golan S, Sopov V, Baniel J et al (2011) Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. J Urol 186:436–441PubMedCrossRef

30.

Goodfellow H, Viney Z, Hughes P et al (2013) Role of Fdg Pet-Ct in the staging of bladder cancer. BJU Int (Epub ahead of print). doi: 10.1111/bju.12608

31.

Goodman OB Jr, Barwe SP, Ritter B et al (2007) Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. Int J Oncol 31:1199–1203PubMed

32.

Gutzeit A, Doert A, Froehlich JM et al (2010) Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 39:333–343PubMedCrossRef

33.

Haseebuddin M, Dehdashti F, Siegel BA et al (2013) 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med 54:699–706PubMedCentralPubMedCrossRef

34.

Heck MM, Souvatzoglou M, Retz M et al (2013) Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging 44(5):340–342

35.

Henry MD, Wen S, Silva MD et al (2004) A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 64:7995–8001PubMedCrossRef

36.

Hitier-Berthault M, Ansquer C, Branchereau J et al (2013) 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int J Urol 20:788–796PubMedCrossRef

37.

Hovels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395PubMedCrossRef

38.

Hricak H, Choyke PL, Eberhardt SC et al (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243:28–53PubMedCrossRef

39.

Issa B (2002) In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging 16:196–200PubMedCrossRef

40.

Jacobs MA, Ouwerkerk R, Petrowski K et al (2008) Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. Top Magn Reson Imaging 19:261–272PubMedCentralPubMedCrossRef

41.

Jadvar H (2013) Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging 40(Suppl 1):5–10CrossRef

42.

Jadvar H, Desai B, Ji L et al (2013) Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med 54:1195–1201PubMedCentralPubMedCrossRef

43.

Kahkonen E, Jambor I, Kemppainen J et al (2013) In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res 19:5434–5443PubMedCrossRef

44.

Kibel AS, Dehdashti F, Katz MD et al (2009) Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27:4314–4320PubMedCrossRef

45.

Kim CK, Park BK, Park W et al (2010) Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom Imaging 35:246–252PubMedCrossRef

46.

Kim JK, Kim KA, Park BW et al (2008) Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging 28:714–719PubMedCrossRef

47.

Krause BJ, Souvatzoglou M, Treiber U (2013) Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 31:427–435PubMedCrossRef

48.

Krause BJ, Souvatzoglou M, Tuncel M et al (2008) The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18–23PubMedCrossRef

49.

Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75PubMedCrossRef

50.

Liedberg F, Bendahl PO, Davidsson T et al (2013) Preoperative staging of locally advanced bladder cancer before radical cystectomy using 3 tesla magnetic resonance imaging with a standardized protocol. Scand J Urol 47:108–112PubMedCrossRef

51.

Liu Y, Hu X, Liu H et al (2013) A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. J Nucl Med 54:2132–2138PubMedCrossRef

52.

Lu YY, Chen JH, Liang JA et al (2012) Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol 81:2411–2416PubMedCrossRef

53.

Mamede M, Ceci F, Castellucci P et al (2013) The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level < 0.5 ng/mL. Clin Nucl Med 38:342–345CrossRef

54.

Manenti G, Squillaci E, Di Roma M et al (2006) In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging. Radiol Med 111:1124–1133PubMedCrossRef

55.

Marzola MC, Chondrogiannis S, Ferretti A et al (2013) Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med 38:26–32CrossRef

56.

Maurer T, Beer AJ, Souvatzoglou M et al (2014) 68Gallium-labelled ligand of prostate-specific membrane antigen (PSMA) for the evaluation of recurrent prostate cancer using PET/CT and PET/MR imaging. Eur Urol (Suppl) (Epub ahead of print)

57.

Maurer T, Beer AJ, Souvatzoglou M et al (2014) Staging of intermediate and high-risk prostate cancer using whole body 68Gallium-labelled ligand of prostate-specific membrane antigen PET/MRI. J Urol (Suppl) (Epub ahead of print)

58.

Maurer T, Horn T, Beer AJ et al (2013) Functional imaging in bladder cancer. Urologe A 52:509–514PubMedCrossRef

59.

Maurer T, Souvatzoglou M, Kubler H et al (2012) Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol 61:1031–1038PubMedCrossRef

60.

Mease RC, Foss CA, Pomper MG (2013) PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 13:951–962PubMedCrossRef

61.

Mertens LS, Bruin NM, Vegt E et al (2012) Catheter-assisted 18F-FDG-PET/CT imaging of primary bladder cancer: a prospective study. Nucl Med Commun 33:1195–1201PubMedCrossRef

62.

Mertens LS, Fioole-Bruining A, Vegt E et al (2013) Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int 112:729–734PubMedCrossRef

63.

Mohsen B, Giorgio T, Rasoul ZS et al (2013) Application of (11) C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int 112:1062–1072PubMedCrossRef

64.

Murphy GP, Elgamal AA, Su SL et al (1998) Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 83:2259–2269PubMedCrossRef

65.

Nanni C, Schiavina R, Boschi S et al (2013) Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging 40(Suppl 1):11–17CrossRef

66.

Nayak B, Dogra PN, Naswa N et al (2013) Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique. Eur J Nucl Med Mol Imaging 40:386–393PubMedCrossRef

67.

Orevi M, Klein M, Mishani E et al (2012) 11C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline. Clin Nucl Med 37:67–72CrossRef

68.

Osborne JR, Akhtar NH, Vallabhajosula S et al (2013) Prostate-specific membrane antigen-based imaging. Urol Oncol 31:144–154PubMedCentralPubMedCrossRef

69.

Panebianco V, Barchetti F, Sciarra A et al (2013) Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol 23:1745–1752PubMedCrossRef

70.

Puech P, Potiron E, Lemaitre L et al (2009) Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 74:1094–1099PubMedCrossRef

71.

Reske SN, Blumstein NM, Neumaier B et al (2006) Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47:1249–1254PubMed

72.

Richter S, Wuest M, Krieger SS et al (2013) Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Nucl Med Biol 40:1025–1034PubMedCrossRef

73.

Rioja Zuazu J, Rodriguez M, Rincon Mayans A et al (2009) Usefulness of PET scans in diagnosing recurrent prostate cancer. Prostate with PSA level < 5 ng/ml. Actas Urol Esp 33:844–852CrossRef

74.

Saokar A, Islam T, Jantsch M et al (2010) Detection of lymph nodes in pelvic malignancies with computed tomography and magnetic resonance imaging. Clin Imaging 34:361–366PubMedCrossRef

75.

Schiavina R, Concetti S, Brunocilla E et al (2013) First case of F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative C-Choline PET/CT: new imaging techniques may expand pioneering approaches. Urol Int 92:242–245PubMedCrossRef

76.

Schoder H, Ong SC, Reuter VE et al (2012) Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer. Mol Imaging Biol 14:245–251PubMedCrossRef

77.

Shariat SF, Ehdaie B, Rink M et al (2012) Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol 61:237–242PubMedCrossRef

78.

Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85PubMed

79.

Souvatzoglou M, Eiber M, Martinez-Moeller A et al (2013) PET/MR in prostate cancer: technical aspects and potential diagnostic value. Eur J Nucl Med Mol Imaging 40(Suppl 1):79–88CrossRef

80.

Souvatzoglou M, Eiber M, Takei T et al (2013) Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 40:1486–1499PubMedCrossRef

81.

Souvatzoglou M, Weirich G, Schwarzenboeck S et al (2011) The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res 17:3751–3759PubMedCrossRef

82.

Stenzl A, Cowan NC, De Santis M et al (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59:1009–1018PubMedCrossRef

83.

Swinnen G, Maes A, Pottel H et al (2010) FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57:641–647PubMedCrossRef

84.

Taoka T, Mayr NA, Lee HJ et al (2001) Factors influencing visualization of vertebral metastases on MR imaging versus bone scintigraphy. AJR Am J Roentgenol 176:1525–1530PubMedCrossRef

85.

Treglia G, Ceriani L, Sadeghi R et al (2013) Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med 1–9

86.

Umbehr MH, Muntener M, Hany T et al (2013) The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64:106–117PubMedCrossRef

87.

Vargas HA, Akin O, Schoder H et al (2012) Prospective evaluation of MRI, (1)(1)C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol 81:4131–4137PubMedCrossRef

88.

Vicente AM, Castrejon AS, Munoz AP et al (2010) Impact of 18F-FDG PET/CT with retrograde filling of the urinary bladder in patients with suspected pelvic malignancies. J Nucl Med Technol 38:128–137PubMedCrossRef

89.

Von Eyben FE, Kairemo K (2013) Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 38(5):305–14CrossRef

90.

Wang L, Hricak H, Kattan MW et al (2006) Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 186:743–748PubMedCrossRef

91.

Watanabe H, Kanematsu M, Kondo H et al (2010) Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging. J Magn Reson Imaging 31:1151–1156PubMedCrossRef

92.

Wondergem M, Van Der Zant FM, Van Der Ploeg T et al (2013) A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 34:935–945PubMedCrossRef

93.

Yerram NK, Volkin D, Turkbey B et al (2012) Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int 110:783–788CrossRef

Titel: Molekulare multimodale Hybridbildgebung des Prostata- und Blasenkarzinoms
verfasst von: PD Dr. T. Maurer
M. Eiber
B.J. Krause
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Die Urologie / Ausgabe 4/2014
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-014-3440-5

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Das GeSRU-Hospitationsprogramm

Mitteilungen der DGU

Berufspolitik BDU

Praktische Studentenausbildung in der Urologie